Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
Condition: Central Nervous System Tumor, Pediatric
MeSH terms: Nervous System Neoplasms; Central Nervous System Neoplasms; Rhabdoid Tumor
Intervention: filgrastim; cisplatin; cyclophosphamide; cytarabine; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide; leucovorin calcium; methotrexate; temozolomide; therapeutic hydrocortisone; vincristine sulfate; radiation therapy; Dactinomycin
Intervention MeSH terms: Calcium, Dietary; Leucovorin; Cytarabine; Dactinomycin; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate; Cyclophosphamide; Temozolomide; Cisplatin; Doxorubicin; Liposomal doxorubicin; Methotrexate; Etoposide; Vincristine; Dexrazoxane; Razoxane; Lenograstim; Calcium; Levoleucovorin
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 25.0
Sex: All
Maximum age: 18 Years
Healthy volunteers: No
Keywords: childhood atypical teratoid/rhabdoid tumor

Summary:

      RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from
      dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage
      tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more
      tumor cells.

      PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination
      chemotherapy together with radiation therapy works in treating young patients with newly
      diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumors.
    

Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary intracranial Central Nervous System (CNS) atypical
             teratoid/rhabdoid tumor OR

          -  Tumor tissue that possesses the INI-1 gene mutation

          -  No metastases that disseminate outside the CNS by abdominal and chest computer
             tomography (CT) scans, kidney imaging, and bone marrow biopsy

               -  No obstruction of cerebrospinal fluid (CSF) flow by CSF flow study

          -  Definitive surgical resection of tumor within the past 35 days

        PATIENT CHARACTERISTICS:

        Age

          -  18 and under

        Performance status

          -  Karnofsky 50-100% OR

          -  Lansky 50-100%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Hemoglobin > 10 g/dL

          -  Absolute neutrophil count > 1,000/mm^3

          -  Platelet count > 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 mg/dL

          -  SGPT < 10 times normal

        Renal

          -  Creatinine ≤ 1.5 times normal

        Other

          -  Willing to have placement of central venous access line

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  Prior steroids allowed

        Radiotherapy

          -  No prior radiotherapy

        Surgery

          -  See Disease Characteristics

        Other

          -  No other prior or concurrent investigational agents

          -  Concurrent anticonvulsant agents allowed